126 related articles for article (PubMed ID: 36621979)
1. Loss of CBX2 causes genomic instability and Wnt activation in high grade serous ovarian carcinoma cells.
Ma Y; Liu L; Wei Z; Zhu M; Huang L; Wang S; Yi X; Ying F; Zhao S; Cai J; Wang Z; Sun S
Mol Carcinog; 2023 Apr; 62(4):479-492. PubMed ID: 36621979
[TBL] [Abstract][Full Text] [Related]
2. CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer.
Wheeler LJ; Watson ZL; Qamar L; Yamamoto TM; Post MD; Berning AA; Spillman MA; Behbakht K; Bitler BG
Oncogenesis; 2018 Nov; 7(11):92. PubMed ID: 30478317
[TBL] [Abstract][Full Text] [Related]
3. In vivo tumor growth of high-grade serous ovarian cancer cell lines.
Mitra AK; Davis DA; Tomar S; Roy L; Gurler H; Xie J; Lantvit DD; Cardenas H; Fang F; Liu Y; Loughran E; Yang J; Sharon Stack M; Emerson RE; Cowden Dahl KD; V Barbolina M; Nephew KP; Matei D; Burdette JE
Gynecol Oncol; 2015 Aug; 138(2):372-7. PubMed ID: 26050922
[TBL] [Abstract][Full Text] [Related]
4. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.
Raab M; Kostova I; Peña-Llopis S; Fietz D; Kressin M; Aberoumandi SM; Ullrich E; Becker S; Sanhaji M; Strebhardt K
Cancer Commun (Lond); 2024 Jan; 44(1):101-126. PubMed ID: 38140698
[TBL] [Abstract][Full Text] [Related]
5. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
[TBL] [Abstract][Full Text] [Related]
6. Effects of Wnt/β-Catenin Signal Pathway Regulated by miR-342-5p Targeting CBX2 on Proliferation, Metastasis and Invasion of Ovarian Cancer Cells.
Dou Y; Chen F; Lu Y; Qiu H; Zhang H
Cancer Manag Res; 2020; 12():3783-3794. PubMed ID: 32547214
[TBL] [Abstract][Full Text] [Related]
7. [Study of the clinical significance of ETAR mRNA expression in high-grade serous ovarian cancer and the inhibitory effect of ETAR derived fusion polypeptide on cancer progression].
Zhang YL; Xia XK; Zhang M
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):930-938. PubMed ID: 38123199
[No Abstract] [Full Text] [Related]
8. The clinical significance and biological function of lncRNA SOCAR in serous ovarian carcinoma.
Guo Q; Wang L; Zhu L; Lu X; Song Y; Sun J; Wu Z; Shi J; Wang Z; Zhou X
Gene; 2019 Sep; 713():143969. PubMed ID: 31299360
[TBL] [Abstract][Full Text] [Related]
9. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
10. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
11. CBX2 is required to stabilize the testis pathway by repressing Wnt signaling.
Garcia-Moreno SA; Lin YT; Futtner CR; Salamone IM; Capel B; Maatouk DM
PLoS Genet; 2019 May; 15(5):e1007895. PubMed ID: 31116734
[TBL] [Abstract][Full Text] [Related]
12. Cbx2 stably associates with mitotic chromosomes via a PRC2- or PRC1-independent mechanism and is needed for recruiting PRC1 complex to mitotic chromosomes.
Zhen CY; Duc HN; Kokotovic M; Phiel CJ; Ren X
Mol Biol Cell; 2014 Nov; 25(23):3726-39. PubMed ID: 25232004
[TBL] [Abstract][Full Text] [Related]
13. High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target.
Wang H; Ye F; Zhou C; Cheng Q; Chen H
PLoS One; 2021; 16(2):e0245733. PubMed ID: 33635867
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM
Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994
[TBL] [Abstract][Full Text] [Related]
15. Cbx2 targets PRC1 to constitutive heterochromatin in mouse zygotes in a parent-of-origin-dependent manner.
Tardat M; Albert M; Kunzmann R; Liu Z; Kaustov L; Thierry R; Duan S; Brykczynska U; Arrowsmith CH; Peters AH
Mol Cell; 2015 Apr; 58(1):157-71. PubMed ID: 25801166
[TBL] [Abstract][Full Text] [Related]
16. A Potent, Selective CBX2 Chromodomain Ligand and Its Cellular Activity During Prostate Cancer Neuroendocrine Differentiation.
Wang S; Alpsoy A; Sood S; Ordonez-Rubiano SC; Dhiman A; Sun Y; Jiao G; Krusemark CJ; Dykhuizen EC
Chembiochem; 2021 Jul; 22(13):2335-2344. PubMed ID: 33950564
[TBL] [Abstract][Full Text] [Related]
17. CBX2 is a functional target of miRNA let-7a and acts as a tumor promoter in osteosarcoma.
Han Q; Li C; Cao Y; Bao J; Li K; Song R; Chen X; Li J; Wu X
Cancer Med; 2019 Jul; 8(8):3981-3991. PubMed ID: 31150156
[TBL] [Abstract][Full Text] [Related]
18. CBX2 depletion inhibits the proliferation, invasion and migration of gastric cancer cells by inactivating the YAP/β-catenin pathway.
Zeng M; Li B; Yang L; Guan Q
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33313949
[TBL] [Abstract][Full Text] [Related]
19. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
[TBL] [Abstract][Full Text] [Related]
20. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.
Xu Y; Zhang Q; Miao C; Dongol S; Li Y; Jin C; Dong R; Li Y; Yang X; Kong B
Cancer Med; 2019 Jan; 8(1):351-362. PubMed ID: 30565428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
